: People with intellectual disabilities (IDs), representing approximately 200 million individuals globally (3% of the world's population), face significant disparities in cancer prevention and care. While cancer remains one of the leading causes of mortality worldwide, the intersection of cancer care and intellectual disability presents unique challenges that demand specialized attention within healthcare systems. This study evaluates the current status and effectiveness of National Cancer Control Programs (NCCPs) for individuals with intellectual disabilities across the European Union. : A systematic analysis was conducted of 27 European Union member states' National Cancer Control Programs between August 2023 and August 2024. The study utilized the International Cancer Control Partnership (ICCP) framework, examining English-language documents and official translations to ensure analytical consistency. : Our analysis reveals that while all 27 EU member states have established NCCPs, significant variations exist in their approach to ID-specific provisions, with implementation scores ranging from 1 (basic) to 3 (comprehensive). Key findings indicate that only 15% of programs have comprehensive ID-specific provisions, while 60% maintain moderate adaptations and 25% offer basic provisions. Specific gaps identified include limited specialized healthcare provider training (present in only 7.5% of programs) and inadequate screening program adaptations. : Based on a quantitative assessment of implementation status and program components, we propose evidence-based recommendations emphasizing the urgent need for enhanced ID-specific provisions in NCCPs.

Download full-text PDF

Source
http://dx.doi.org/10.3390/healthcare13050456DOI Listing

Publication Analysis

Top Keywords

cancer control
16
national cancer
12
control programs
12
intellectual disabilities
12
id-specific provisions
12
people intellectual
8
european union
8
cancer
7
programs
5
analysis european
4

Similar Publications

Organelle-targeted BODIPY-conjugated platinum(IV) anticancer prodrugs for overcoming drug resistance.

Dalton Trans

March 2025

Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang 330022, China.

Platinum-based chemotherapy, despite being a cornerstone of cancer treatment, faces significant challenges due to acquired drug resistance. To address this issue, we have designed three organelle-targeting platinum(IV) prodrugs conjugated with BODIPY fluorophores, enabling spatiotemporal control through green light irradiation. These BODIPY-Pt(IV) conjugates exhibit excellent stability in PBS buffer, demonstrating resilience under physiological conditions.

View Article and Find Full Text PDF

Aims: Osteoarthritis (OA) is a widespread chronic degenerative joint disease with an increasing global impact. The pathogenesis of OA involves complex interactions between genetic and environmental factors. Despite this, the specific genetic mechanisms underlying OA remain only partially understood, hindering the development of targeted therapeutic strategies.

View Article and Find Full Text PDF

Introduction: Colorectal cancer (CRC) incidence is increasing in Uganda. Despite this, and the disproportionately high burden of early onset and late-stage CRC cases, no CRC screening program exists in Uganda. To guide and inform future CRC prevention efforts, interviews with key stakeholders were undertaken to better understand the perceived barriers and opportunities relevant to the development and implementation of a CRC screening program in Uganda.

View Article and Find Full Text PDF

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia.

Haematologica

March 2025

Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra.

Continuous treatment with ibrutinib not only exerts tumor control but also enhances T cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of Tregs and Tfh cells normalized to levels observed in healthy donors.

View Article and Find Full Text PDF

Primary esophageal melanoma (PEM) is a rare and aggressive malignancy with limited treatment options. Due to its rarity, no standardized guidelines exist for managing oligometastatic recurrence, particularly in resource-limited settings. We present a case of a 60-year-old male with PEM who underwent esophagectomy followed by surgical resection of an adrenal metastasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!